Acurx Pharmaceuticals Llc Stock Alpha and Beta Analysis
| ACXP Stock | USD 1.15 0.01 0.88% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Acurx Pharmaceuticals LLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Acurx Pharmaceuticals over a specified time horizon. Remember, high Acurx Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Acurx Pharmaceuticals' market risk premium analysis include:
Beta 0.76 | Alpha (0.95) | Risk 3.8 | Sharpe Ratio (0.25) | Expected Return (0.95) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Acurx |
Acurx Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Acurx Pharmaceuticals market risk premium is the additional return an investor will receive from holding Acurx Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Acurx Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Acurx Pharmaceuticals' performance over market.| α | -0.95 | β | 0.76 |
Acurx Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Acurx Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Acurx Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Acurx Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Acurx Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Acurx Pharmaceuticals shares will generate the highest return on investment. By understating and applying Acurx Pharmaceuticals stock market price indicators, traders can identify Acurx Pharmaceuticals position entry and exit signals to maximize returns.
Acurx Pharmaceuticals Return and Market Media
The median price of Acurx Pharmaceuticals for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 is 1.96 with a coefficient of variation of 12.4. The daily time series for the period is distributed with a sample standard deviation of 0.24, arithmetic mean of 1.9, and mean deviation of 0.16. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 1030 PM PT Sept... | 09/09/2024 |
2 | New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 630 PM EST | 10/11/2024 |
3 | New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Suppo... | 10/14/2024 |
4 | Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference | 10/21/2024 |
5 | Acquisition by Robert DeLuccia of 250000 shares of Acurx Pharmaceuticals at 3.15 subject to Rule 16b-3 | 10/22/2024 |
6 | New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tanks Kevin Harrington, A... | 10/31/2024 |
7 | Acquisition by Donohue James J. of 50000 shares of Acurx Pharmaceuticals at 6.18 subject to Rule 16b-3 | 11/01/2024 |
8 | Acurx Pharmaceuticals Posts Earnings Results, Beats Expectations By 0.06 EPS | 11/13/2024 |
9 | Acurx Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ... | 11/14/2024 |
10 | Bitcoin Hits New All-Time High Above 98,000 As Spot ETFs Crack 100 Billion Net Asset Value Milestone | 11/21/2024 |
About Acurx Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Acurx or other stocks. Alpha measures the amount that position in Acurx Pharmaceuticals LLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2024 (projected) | Current Ratio | 15.71 | 2.41 | Net Debt To EBITDA | 0.75 | 0.5 |
Acurx Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Acurx Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Acurx Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Acurx Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Acurx Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Acurx Pharmaceuticals' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Acurx Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.